Author: admin

– Recommendation based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life versus placebo CARLSBAD, Calif., Oct. 21, 2024  /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announc

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: